ArticleBMC cancer2015
Liposome encapsulated zoledronate favours M1-like behaviour in murine macrophages cultured with soluble factors from breast cancer cells.
Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Evaluation of the effect of resveratrol on bone healing after tooth extraction in rats treated with zoledronic acid.Scientific reports · 2025Article
- Progress in reeducating tumor-associated macrophages in tumor microenvironment.Discover oncology · 2024Review
- Nanotherapeutics for Macrophage Network Modulation in Tumor Microenvironments: Targets and Tools.International journal of nanomedicine · 2024Review
- Biomimetic Systems Involving Macrophages and Their Potential for Targeted Drug Delivery.Biomimetics (Basel, Switzerland) · 2023Review
- Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy.Theranostics · 2022Review
- Emerging Nanoparticle Strategies for Modulating Tumor-Associated Macrophage Polarization.Biomolecules · 2021Review
- Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy.Pharmaceutics · 2021Review
- Review
- Recent Advancements in Nanomedicine for 'Cold' Tumor Immunotherapy.Nano-micro letters · 2021Review
- Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment.Frontiers in bioengineering and biotechnology · 2021Review
- Tumor-associated macrophages: Role in the pathological process of tumorigenesis and prospective therapeutic use (Review).Biomedical reports · 2020Review
- Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment.Frontiers in immunology · 2020Review
- Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Biology of Bone Sarcomas and New Therapeutic Developments.Calcified tissue international · 2018Review
- Article
- Design and Biological Evaluation of Delivery Systems Containing Bisphosphonates.Pharmaceutics · 2016Review
- SHIP represses lung inflammation and inhibits mammary tumor metastasis in BALB/c mice.Oncotarget · 2016Article
- Human breast cancer cells educate macrophages toward the M2 activation status.Breast cancer research : BCR · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumour stromal macrophages differentiate to tumour-associated macrophages (TAMs) with characteristics of immunosuppressive M2-type macrophages, having a central role in promoting tumour vascularisation, cancer cell dissemination and in suppressing anti-cancer immune responses. Bisphosphonates (BPs) are a group of drugs commonly used as anti-resorptive agents. Further, nitrogen containing BPs like Zoledronate (ZOL), are known to cause unspecific inflammatory reactions hence the hypothesis that its use could modulate TAMs polarization toward a more inflammatory phenotype.
methodsWe studied the in vitro polarization of J774 murine macrophages upon culture in 4T1 breast cancer cell-conditioned medium (4T1CM) and stimulation with LPS and free and liposome-encapsulated bisphosphonates.
resultsIn this system, breast cancer soluble factors reduced the pro-inflammatory activation of macrophages but increased the secretion of matrix metalloproteinases (MMPs). In the presence of 4T1CM, a non-cytotoxic dose of liposome-encapsulated ZOL (ZOL-LIP) enhanced the expression of iNOS and TNF-α, markers of M1 activation, but did not diminish the expression of M2-type markers. In contrast, clodronate treatment either as a free drug (CLO) or liposome-encapsulated (CLO-LIP) decreased the expression of the M1-type markers and was highly cytotoxic to the macrophages.
conclusionsBreast cancer cells soluble factors modulate macrophages toward M2 activation state. Bisphosphonates may be applied to counteract this modulation. We propose that ZOL-LIP may be suitable for favouring cytotoxic immune responses by TAMs in breast cancer, whereas CLO-LIP may be appropriate for TAM depletion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.